The study, recently published in the Nature journal Scientific Reports, showed that as levels of calprotectin, an inflammatory marker, increased in the volunteer study participants’ stool samples, so did the amount of amyloid plaque accumulating in the brains of those with Alzheimer’s disease....
Dr. Howard Bailey, director of the Madison-based cancer treatment and research organization, spoke this week during a meeting of the Wisconsin Technology Council’s Innovation Network. He emphasized the progress being made in understanding and developing more effective treatments for the disease, as well as new...
Lupus significantly and disproportionately impacts Black, Hispanic and Asian patients, but these populations are underrepresented in clinical trials for the disease....
Testing a person’s blood for a type of protein called phosphorylated tau, or p-tau, could be used to screen for Alzheimer’s disease with “high accuracy,” even before symptoms begin to show, a new study suggests....
As new treatments reach the market, a problem appears: real-world research shows dissatisfying outcomes and access disparities. One US study reveals that within the early years of a novel interventional device usage, women fare significantly worse than men, even after accounting for underlying differences....
A growing study in Wisconsin is focused on understanding Alzheimer’s disease and its impact on the African American community. ...
Deming, ACI/Schwenn Family associate professor in the Division of Hematology, Medical Oncology and Palliative Care at UW School of Medicine and Public Health, did not plan to treat patients when he started medical school — much of his experience had been in laboratory medicine, and...
Topics highlighted include diversity and inclusion, decentralized clinical trial (DCT) elements, workforce challenges, and a possible role for sponsors and contract research organizations (CROs) in supporting outreach by sites based in diverse communities....
The five-year study will provide state-of-the-art imaging and blood-based biomarkers for researchers around the world to study and advance the field of Alzheimer’s and related dementias. The work is also designed to shed light on mixed dementia, where more than one neurological disease is contributing...
The US Food and Drug Administration (FDA) finalized guidance on drug development programs for rare diseases, eliminating a section on natural history and providing additional considerations related to patient and caregiver input and pediatric populations....
